Placeholder Banner

BIO Statement on the United States-Mexico-Canada Agreement

October 4, 2018

Washington, D.C. (October 4, 2018) – Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the United States-Mexico-Canada Agreement (USMCA):

“BIO supports the USMCA and appreciates the Administration’s efforts to prioritize biotechnology innovation, including provisions that update intellectual property protections and agricultural market access to 21st century standards.

“Strong and dependable intellectual property standards are critical to fueling innovation, attracting investment, and ensuring that patients, farmers, and consumers around the globe have access to the next generation of biotechnology breakthroughs. The USMCA represents an important step in bringing Mexico and Canada closer to high U.S. standards that have made us the world leader in biotechnology innovation.

“The U.S., Mexico and Canada also have a long history of cooperation in the area of agricultural biotechnology, the USMCA builds on this by advancing provisions to facilitate trade and ensure cooperation on future innovation in biotechnology.

“Thanks to the Administration’s leadership, the U.S. and our neighboring countries will continue to drive global innovation, ingenuity and ground-breaking science.

“The USMCA sets important new standards for U.S. trade policy by ensuring trading partners establish policies that protect, respect, and advance the hard work and investment needed to bring new biotechnology innovations from the lab to the marketplace.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…